Every 10-Q that Tandem Diabetes Care, Inc. (TNDM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TNDM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNDM filings page.
Tandem Diabetes Care reported higher sales and a smaller loss for the quarter ended June 30, 2026. Sales rose to $254.6 million from $240.7 million a year earlier, with first-half 2026 sales of $501.8 million. Q2 gross profit increased to $144.8 million, while operating expenses declined to $158.6 million due to the absence of prior-year litigation and acquired in-process R&D charges. The Q2 operating loss narrowed to $13.8 million, and net loss to $21.2 million, or $0.31 per share, compared with a $52.4 million loss, or $0.78 per share, in Q2 2025. For the first half, net loss improved to $41.6 million from $183.0 million.
At June 30, 2026, cash and cash equivalents were $62.8 million and short-term investments $393.2 million, with total assets of $1.15 billion and stockholders’ equity of $130.4 million. Long-term convertible senior notes increased to $602.6 million after issuing $300.0 million of 0.00% notes due 2032 and entering related capped call transactions. Operating cash outflow was $23.6 million for the first half, while financing activities provided $276.3 million. Tandem expanded its equity method investment in CeQur SA by CHF 64.0 million ($81.4 million) and continues to hedge foreign currency exposure with forward contracts. Strategically, the company is shifting U.S. reimbursement toward a pay-as-you-go pharmacy model, submitted a 510(k) for Tandem Mobi tubeless capability, and is managing infusion set supply constraints expected to persist through 2026.
Tandem Diabetes Care reported higher sales and a sharply smaller loss for the quarter ended March 31, 2026. Sales rose to $247.2 million from $234.4 million, driven by pump and supply growth in both the United States and international markets. U.S. sales reached $160.8 million, while international sales were $86.4 million.
Gross profit increased to $136.8 million and gross margin improved to 55% from 51%, helped by better pricing, product mix, foreign exchange and lower material costs. Operating expenses dropped significantly to $154.2 million from $239.3 million, mainly because the prior year included $75.2 million of acquired in‑process research and development and lease impairment and restructuring charges that did not repeat.
Net loss narrowed to $20.4 million from $130.6 million, or $0.30 per share versus $1.97. Cash and cash equivalents rose to $179.3 million and short‑term investments to $390.9 million, supported by a new $300.0 million 0.00% Convertible Senior Notes due 2032, which increased total long‑term convertible debt to $601.8 million.
Tandem Diabetes Care reported Q3 2025 results. Sales were $249.3 million, up slightly year over year, with gross profit of $134.3 million. Operating loss was $22.9 million, and net loss narrowed to $21.2 million (basic and diluted loss per share $0.31) from $23.3 million a year ago.
For the first nine months, sales reached $724.4 million and net loss was $204.1 million, reflecting $75.2 million of acquired in‑process R&D, $20.0 million of litigation and settlement expense, and $9.6 million of equity‑method losses. Cash and cash equivalents were $91.9 million and short‑term investments were $227.2 million. Long‑term convertible notes, net, were $309.6 million, and stockholders’ equity was $133.0 million.
Operating cash flow was a use of $19.5 million year‑to‑date, with $87.9 million provided by investing activities and $46.0 million used in financing, including $40.8 million to settle the 2025 notes. The company entered a cross‑license with Roche, agreeing to pay $36.0 million over four years; $13.3 million was capitalized as an intangible asset, and a $31.6 million present‑value liability was recorded. As of November 4, 2025, shares outstanding were 67,802,359.